drugset / Trial / NCT03785925
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.
Timeline
- Start
- 2019-04-29
- Primary completion
- 2022-02-09
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |